Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dasatinib as tablets
Dasatinib as · 1 trial · 1 indication
Single-dose pharmacokinetic parameters, including Cmax, were derived using noncompartmental methods from plasma dasatinib concentration-time data.
Single-dose pharmacokinetic, such as AUC(0-T),parameters were derived using noncompartmental methods from plasma dasatinib concentration-time data.
Single-dose pharmacokinetic parameters, such as AUC(0-INF) were derived using noncompartmental methods from plasma dasatinib concentration-time data.
| Arm | Type | Description |
|---|---|---|
| Dasatinib, 100 mg as tablets + water | OTHER | Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2. |
| Dasatinib, 100 mg as liquid + water | OTHER | Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2. |
| Dasatinib, 100 mg as tablets in orange juice + water | OTHER | Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2. |
| Name | Type | Description |
|---|---|---|
| Dasatinib as tablets | DRUG | 2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day |
| Dasatinib as liquid | DRUG | 100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day |
| Dasatinib as dispersed tablets | DRUG | 2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day. |
Key Inclusion Criteria: * Healthy participants, defined as having no clinically relevant deviation from normal in medical history, physical examination, electrocardiogram (ECG) findings, and clinical laboratory tests findings. * Body mass index of 18 to 32 kg/m\^2, inclusive * Age from 18 to 55 yea...
Dasatinib as refers to a tablet formulation of dasatinib, a small molecule drug developed by Bristol-Myers Squibb Company (ticker BMY). It is an investigational oral therapy studied in a Phase 1 pharmacokinetic trial comparing blood levels of the tablet formulation with liquid and tablet-dispersed formulations in healthy participants.
Dasatinib as targets ABL1 and BCR. It belongs to the inhibitor class of small molecule drugs, meaning it works by inhibiting the activity of these molecular targets. This targeted mechanism underlies its development as an oral tablet formulation studied in pharmacokinetic research.
Dasatinib as is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is responsible for the tablet formulation of dasatinib evaluated in the clinical program.
Dasatinib as is in Phase 1 clinical development. It is an investigational drug and is not approved. The Phase 1 program includes one completed trial with 141 participants, and no active trials are currently listed.
Dasatinib as has been studied in one completed Phase 1 trial, NCT01392703. This pharmacokinetic study compared blood levels of dasatinib in healthy participants who received the tablet formulation with those who received liquid and tablet-dispersed formulations. It enrolled 141 participants in the United States and was controlled and randomized.
Yes, Dasatinib as is also known as Dasatinib as tablets. Both names refer to the same tablet formulation of dasatinib developed by Bristol-Myers Squibb Company under the ticker BMY.